Centerpoint Advisors’s Precigen PGEN Stock Holding History

Centerpoint Advisors’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-150	Closed	-$1K	–	261
2018 Q4	$1K	Hold	150	–	–	﹤0.01%	241
2018 Q3	$3K	Hold	150	–	–	﹤0.01%	206
2018 Q2	$2K	Hold	150	–	–	﹤0.01%	317
2018 Q1	$2K	Hold	150	–	–	﹤0.01%	213
2017 Q4	$2K	Buy	+150	New	+$2.23K	﹤0.01%	177

Other funds holding PGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Centerpoint Advisors's PGEN Position: Q1 2019 in Review

Centerpoint Advisors sold out of Precigen (PGEN) in Q1 2019, closing a stake of 150 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in PGEN in Q4 2017 and held it in 5 quarters. The position peaked at $3K in Q3 2018. 166 funds tracked by Wall St. Rank hold PGEN as of Q1 2019.

Centerpoint Advisors reported no remaining Precigen position as of Q1 2019 after selling out during the quarter.
Centerpoint Advisors sold 150 Precigen shares in Q1 2019, an estimated $1K.
Centerpoint Advisors first reported a position in Precigen in Q4 2017 and held it in 5 quarters.
Centerpoint Advisors's Precigen position peaked at $3K in Q3 2018.
166 funds tracked by Wall St. Rank held Precigen as of Q1 2019.

Based on Centerpoint Advisors's 13F filing for Q1 2019, filed 25 Apr 2019.